After an analysis of their protein structures, EPAS1/HIF-2α was selected for virtual screening as the drug target of an anti-ccRCC therapy by one neural network-based molecular feature model (DMPNN) and an optimal machine learning classifier (GBDT), DMPNN + GBDT [24] to predict potential compounds specific to EPAS1 protein. Here, EPAS1 is linked to nonpapillary renal cell carcinoma.